| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2361497-72-3 | [Synonyms]
CPL207280
Benzenepropanoic acid, 4-[(2,3-dimethyl-2-buten-1-yl)oxy]-β-1-propyn-1-yl-, (βS)- | [Molecular Formula]
C18H22O3 | [MOL File]
2361497-72-3.mol | [Molecular Weight]
286.37 |
| Hazard Information | Back Directory | [Uses]
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes[1][2]. | [in vivo]
PL207280 (10 mg/kg; p.o.; single dose) exhibits hypoglycemic effects in Wistar Han rats, with (3 mg/kg; p.o.; single dose) pharmacokinetic parameters of Cmax, Tmax, and T1/2 being 1699 ng/mL, 1 h, and 1.41 h, respectively[1]. | [References]
[1] Mach M, et al. Discovery and development of CPL207280 as new GPR40/FFA1 agonist. Eur J Med Chem. 2021;226:113810. DOI:10.1016/j.ejmech.2021.113810
[2] Bazydlo-Guzenda K, et al. CPL207280-a novel GPR40/FFA1-specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals[J]. Molecular Pharmacology, 2021. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|